2026.02. 10 本文字数：2754，阅读时长大约4分钟 作者 | 第一财经 黄思瑜 2月10日，随着新股电科蓝天（688818.SH）上市，科创板上市公司总数达到603家，总市值达到 11.44万亿元。 截至目前，科创板逾390家公司以业绩预告或快报形式披露了2025年度预计业绩情况，占板块公司 总数的超六成；另有1家公司披露了科创板2025年度首份年报。从细分行业表现看，集成电路、生 物医药行业景气度回升。 科创综指为观察科创板整体情况和发展态势提供了全局性的视角。截至2月10日，科创综指样本数量 达580只，市值覆盖度超过90%，总市值高于100亿元的科创综指成份股权重占比较发布时提升 15.1%。 东吴证券首席经济学家、研究所联席所长芦哲对第一财经称，预期未来3～5年，科创板总市值有望 翻倍，科创综指将同步成长为"万亿级产品规模、千亿级日成交"的核心宽基指数，不仅与沪深 300、创业板指并驾齐驱，更可能率先完成"本土指数—跨境ETF—全球定价"的三级跳，成为中国科 技创新实力对外展示的"首张名片"。 391家公司"交卷"，六成预增 目前，科创板上市公司数量合计603家，包括61家未盈利企业、9家 ...

2月10日，科创板又迎来新兵电科蓝天。目前，科创板上市公司总数达到603家。 作为中国"硬科技"企业的聚集地，科创板的板块产业图谱与现代化产业体系建设同向而行，尤其在新一 代信息技术、生物医药、高端装备制造等战略性新兴产业，已形成"链主引领、上下协同"的发展格局。 科创综指为观察科创板整体情况和发展态势提供了全局性的视角。推出一年来，科创综指的市场关注度 持续提升，截至2026年2月10日，科创综指样本数量达580只，市值覆盖度超过90%，总市值高于100亿 元的科创综指成份股权重占比较发布时提升15.1%，成长效应显著。 科创综指已成为与上证指数、深证成指、创业板指并列的A股四大核心宽基指数，为境内外投资者观测 和分享中国新质生产力发展红利提供了重要工具。 科创板近六成公司预告净利润同比增长 科创综指是定位于覆盖科创板全市场的综合指数，板块市值覆盖度超过90%。可以说，科创综指是分享 科创板公司成长发展成果的有力指标。 截至2026年2月9日，科创板共有391家公司以业绩预告或快报形式披露了2025年度预计业绩情况，占板 块公司总数的六成以上；另有1家公司芯导科技披露了科创板2025年度首份年报，以营收同比 ...

"未来3～5年科创综指相关产品规模和体量仍有巨大发展空间。" 2月10日，随着新股电科蓝天（688818.SH）上市，科创板上市公司总数达到603家，总市值达到11.44万 亿元。 截至目前，科创板逾390家公司以业绩预告或快报形式披露了2025年度预计业绩情况，占板块公司总数 的超六成；另有1家公司披露了科创板2025年度首份年报。从细分行业表现看，集成电路、生物医药行 业景气度回升。 科创综指为观察科创板整体情况和发展态势提供了全局性的视角。截至2月10日，科创综指样本数量达 580只，市值覆盖度超过90%，总市值高于100亿元的科创综指成份股权重占比较发布时提升15.1%。 东吴证券首席经济学家、研究所联席所长芦哲对第一财经称，预期未来3～5年，科创板总市值有望翻 倍，科创综指将同步成长为"万亿级产品规模、千亿级日成交"的核心宽基指数，不仅与沪深300、创业 板指并驾齐驱，更可能率先完成"本土指数—跨境ETF—全球定价"的三级跳，成为中国科技创新实力对 外展示的"首张名片"。 391家公司"交卷"，六成预增 目前，科创板上市公司数量合计603家，包括61家未盈利企业、9家特殊股权架构企业、7家红筹企业、 ...

截至2026年2月9日，科创板中共有391家公司以业绩预告或快报形式披露了2025年度业绩预测。已披露业绩预测的科创板公司中，近六成公司净利润实现 同比增长，其中39家净利润大幅增长100%以上、51家扭亏为盈。科创成长层企业中，寒武纪、奥比中光、精进电动、诺诚健华4家公司预计将在年报披露 后实现"摘U"。 从细分行业表现看，科创板集成电路、生物医药行业景气度回升。其中，集成电路产业受人工智能等新兴应用需求拉动，延续较高景气度，87家已披露业 绩预测的公司，合计净利润同比增加约99.49亿元，57家公司业绩预增或扭亏为盈。创新药行业受益于BD交易频出、出海提速，商业化进程显著加快，26 家公司合计净利润增加14.49亿元，18家披露营业收入的公司合计实现营业收入241.57亿元，同比增长34.9%。 科创综指也是分享改革红利的重要牵引。科创板自设立以来先后推进试点注册制、"科创板八条"、"科创板1+6"三轮系统性改革，着力提高资本市场制度 包容性、适应性。截至2月10日，科创板累计支持61家未盈利企业、9家特殊股权架构企业、7家红筹企业、23家第五套标准企业上市。未盈利上市企业中 22家上市后成功盈利"摘U" ...

本报讯 （记者毛艺融）2026年2月10日，科创板又迎来"新兵"中电科蓝天科技股份有限公司。目前，科 创板上市公司总数达到603家。作为中国"硬科技"企业的聚集地，科创板的板块产业图谱与现代化产业 体系建设同向而行，尤其在新一代信息技术、生物医药、高端装备制造等战略性新兴产业，已形成"链 主引领、上下协同"的发展格局。 科创综指为观察科创板整体情况和发展态势提供了全局性的视角。推出一年来，科创综指的市场关注度 持续提升，截至2026年2月10日，科创综指样本数量达580只，市值覆盖度超过90%，总市值高于100亿 元的科创综指成份股权重占比较发布时提升15.1%，成长效应显著。科创综指已成为与上证指数、深证 成指、创业板指并列的A股四大核心宽基指数，为境内外投资者观测和分享中国新质生产力发展红利提 供了重要工具。 已披露科创板公司 其一，集成电路产业受人工智能等新兴应用需求拉动，延续较高景气度。87家公司披露业绩情况，受益 于人工智能等新兴应用场景拓展，合计净利润同比增加约99.49亿元，57家公司业绩预增或扭亏为盈。 其二，创新药行业BD（商务拓展）交易频出、出海提速，商业化进程显著加快，招采回暖推动制药类 ...

Market Overview - A-shares experienced narrow fluctuations, with the Sci-Tech Innovation Board showing strong performance, particularly in AI applications and computing chips [1] - The Hong Kong stock market saw a significant rebound in the pharmaceutical sector, with the Hong Kong Innovation Drug ETF (520880) reaching a peak increase of 3.86% and closing up 2.9% [3][5] ETF Performance - The Hong Kong Innovation Drug ETF (520880) recorded a trading volume of 5.9 billion, while the Hong Kong Medical ETF (159137) rose by 2.1%, marking its sixth consecutive day of gains [2][3] - The Sci-Tech Artificial Intelligence ETF (589520) increased by 1.81%, with a peak rise of over 2.4% during the trading session [8] Industry Insights - The Chinese innovative drug sector is experiencing a dual breakthrough in internationalization and commercialization, with over 70% of innovative drug companies reporting positive revenue growth [6][7] - Significant collaborations in the innovative drug space include a strategic partnership between Innovent Biologics and Eli Lilly, valued at up to $8.85 billion, and a $18.5 billion collaboration between CSPC Pharmaceutical and AstraZeneca [6] AI and Technology Developments - ByteDance's recent launches, including the Seedance 2.0 video generation model and Seedream 5.0 image generation model, have generated significant interest in the AI sector [11] - The Sci-Tech Artificial Intelligence ETF (589520) has a substantial exposure to ByteDance, with a weight of 29.42% in its index [11][13] Semiconductor and Chip Industry - The semiconductor equipment industry is experiencing an upward trend, with projected sales growth of 26% in 2026, reaching $791.7 billion [17] - The Sci-Tech Chip ETF (589190) is positioned to benefit from the ongoing "super cycle" in the semiconductor industry, with a focus on domestic production and expansion [15][17] Investment Strategy - Analysts suggest that the current market conditions present a favorable opportunity for investment in innovative drugs and AI sectors, with a recommendation to focus on ETFs that track these industries [7][19] - The Sci-Tech Chip ETF has shown a strong annualized return of 17.93%, outperforming other semiconductor indices [19][20]

Group 1 - A-shares experienced narrow fluctuations, with the Sci-Tech Innovation Board performing well, particularly in AI applications and computing power chips [1][25] - The Hong Kong stock market saw a significant rebound in the pharmaceutical sector, with the Hong Kong Innovation Drug ETF (520880) reaching a peak increase of 3.86% and closing up 2.9% [3][29] - The Hong Kong Medical ETF (159137) also performed well, gaining 2.1% and achieving six consecutive days of increases [3][29] Group 2 - The innovation drug sector is benefiting from a surge in business development (BD) overseas and commercial success, with major collaborations announced, including a partnership between Innovent Biologics and Eli Lilly worth up to $8.85 billion [6][29] - Over 70% of innovative drug companies are expected to achieve positive revenue growth in 2025, with notable companies like BeiGene reporting revenues exceeding 36 billion yuan [7][30] - The Chinese innovative drug industry is entering a phase of commercial success and internationalization, with a focus on the entire industry chain, including CXO and research services [7][30] Group 3 - ByteDance's recent releases, including the Seedance 2.0 video generation model and the Seedream 5.0 image generation model, have positively impacted the Sci-Tech Artificial Intelligence ETF (589520), which saw a price increase of 1.81% [10][31] - The ETF's composition includes significant holdings in domestic AI companies, with ByteDance accounting for over 29% of the index [11][35] - Analysts are optimistic about AI investment opportunities, citing increased capital expenditures from tech giants and a growing demand for AI applications [11][35] Group 4 - The semiconductor and storage chip sectors are experiencing a "super cycle," with companies like Chipone Technology reaching historical highs [15][38] - The global memory price is expected to surge by 80% to 90% in Q1 2026, driven by AI demand, with the storage market projected to reach $551.6 billion [17][39] - The semiconductor equipment industry is also on the rise, with total sales expected to grow by 26% in 2026, indicating a strong market outlook [17][40]

Group 1 - The core viewpoint is that the Hong Kong pharmaceutical sector is experiencing a strong resurgence, driven by the innovative drug industry chain, particularly led by Innovent Biologics [1][8] - The Hong Kong Stock Connect Innovative Drug ETF (520880) reached a peak of 3.86% and closed up 2.9%, recovering the 20-day moving average with a trading volume of 590 million yuan [1][8] - The Hong Kong Stock Connect Medical ETF (159137), which has a high CXO content, rose by 2.1%, marking its sixth consecutive day of gains [1][8] Group 2 - The Chinese innovative drug sector is witnessing a robust international expansion, with significant business development (BD) transactions occurring [4][10] - Notable collaborations include Innovent Biologics' announcement of a global strategic partnership with Eli Lilly worth up to $8.85 billion, including an upfront payment of $350 million [4][10] - In January, CSPC Pharmaceutical Group entered a platform-level collaboration with AstraZeneca valued at up to $18.5 billion, while Rongchang Biologics secured a $5.6 billion licensing deal with AbbVie, showcasing the global competitiveness of Chinese innovative drugs [4][10] Group 3 - The Chinese innovative drug industry is entering a commercialization phase, with over 70% of innovative drug companies achieving positive revenue growth by 2025 [5][11] - BeiGene reported revenue exceeding 36 billion yuan, demonstrating strong commercialization capabilities [5][11] - Leading companies like Innovent Biologics and Rongchang Biologics have achieved annual breakeven, while Elysium has reported over 2 billion yuan in net profit attributable to shareholders, indicating a transition from R&D investment to performance realization [5][11] Group 4 - Open Source Securities expresses a positive outlook on the innovative drug sector and its supply chain (CXO + research services), as well as emerging national strategic industries such as AI, brain-computer interfaces, and biomanufacturing [5][11] - The Hong Kong pharmaceutical sector has adjusted for nearly two quarters, presenting an attractive investment opportunity [5][11] - Investors are encouraged to consider the Hong Kong Stock Connect Innovative Drug ETF (520880) and its associated funds, which focus on innovative drug research companies, with the top ten weighted stocks accounting for over 73% [5][11]

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical industry [1] Core Insights - The A-share innovative drug sector saw a decline of 1.32% this week, outperforming the CSI 300 index by 0.02 percentage points, while the biopharmaceutical sector rose by 0.04% [2][14] - The Hong Kong innovative drug sector decreased by 1.45%, outperforming the Hang Seng Index by 1.57 percentage points [19] - The XBI index in the US increased by 0.64%, with a cumulative increase of 47.35% over the past six months [3][19] Summary by Sections A-share and Hong Kong Innovative Drug Sector Performance - A total of 56 stocks rose and 88 stocks fell in the innovative drug sector across mainland China and Hong Kong [2] - The top three gainers were China Antibody-B (+22.79%), Yiteng Jiahe (+14.00%), and Nuocheng Jianhua (+12.24%) [2][13] - The bottom three performers were Yaojie Ankang-B (-14.58%), Shuanglu Pharmaceutical (-13.95%), and Xin Nuowei (-12.53%) [2][13] Recent Approvals and Clinical Trials - In February, four innovative drugs were approved for market in China, with no new indications approved [4][22] - In the US, one NDA was approved, with no BLA approvals reported [5][40] - No innovative drugs were approved in Europe or Japan during this period [5][29][34] Global Innovative Drug Transactions - A total of 19 significant transactions occurred globally, with four notable deals disclosed [6][43] - Key transactions included a $1.5 billion agreement between Saintgen Biotech and Genentech, and a $388 million deal between Fuhong Hanlin and Eisai [6][43] Market Data - The total market capitalization of the pharmaceutical industry is approximately 53,087.87 billion [11] - The industry P/E ratio (TTM) stands at 37.3, compared to the CSI 300's P/E ratio of 14.0 [11]

Core Viewpoint - The A-share market is experiencing a strong upward trend, particularly in the innovative drug sector, with significant gains in the ChiNext Innovative Drug ETF [1][3]. Group 1: Market Performance - As of 11:08 on February 10, the ChiNext Innovative Drug ETF (589120) surged by 2%, marking a potential two-day consecutive rise [1]. - Major component stocks of the ETF, such as Rongchang Biopharma and Baili Tianheng, saw increases exceeding 5%, while others like Baijie Shenzhou rose over 4% [3]. Group 2: Key Component Stocks - The top ten component stocks of the ChiNext Innovative Drug ETF include: - J-Z**KD with a 4.04% increase and an estimated weight of 10.43% - Baili Tianheng with a 5.10% increase and an estimated weight of 7.89% - Rongchang Biopharma with a 5.51% increase and an estimated weight of 6.35% [4]. Group 3: Industry Developments - Innovent Biologics announced the approval of its ICP-538, a VAV1 molecular glue degrader, for clinical research, marking it as the first of its kind in China and the second globally [4]. - Baili Tianheng's recent shareholder meeting approved significant resolutions, including the issuance of debt financing tools and extending the validity of H-share issuance [5]. Group 4: Strategic Collaborations - Innovent Biologics entered a strategic partnership with Eli Lilly to advance the global development of innovative drugs in oncology and immunology, receiving an upfront payment of $350 million and potential milestone payments totaling up to $8.5 billion [5]. Group 5: Industry Growth and Trends - The Chinese innovative drug sector is transitioning from "pipeline expectations" to "performance realization," with over 70% of companies projected to achieve revenue growth by 2025 [8]. - The total value of License-out transactions for Chinese innovative drugs skyrocketed from $2.562 billion in 2017 to an estimated $140.274 billion by 2025, indicating a significant increase in global recognition [6]. Group 6: Investment Opportunities - Three key investment themes for 2026 in the innovative drug sector include: 1. Accelerated BD (Business Development) overseas, focusing on ADC, dual antibodies, and GLP-1RA [9]. 2. Policy support for innovative drug development, enhancing commercialization opportunities [9]. 3. Monitoring critical clinical data and commercialization milestones for new drugs [10].